[177Lu]Lu DOTA-ABM-5G

N/A

Report date: 2025/11/20 16:00:47

Base Information

Drug Name[177Lu]Lu DOTA-ABM-5G
Drug Alias Name[177Lu]Lu DOTA-ABM-5G
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionPositron-emission tomography enhancers
TargetsNot applicable
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of California DavisUnited States Department Of Defense
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California DavisUnited States Department Of Defense
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A